Current and emerging treatments for vitiligo - 14/12/17

Doi : 10.1016/j.jaad.2016.11.010

Michelle Rodrigues, MBBS(Hons), FACD ^a,^b,^⁎ , Khaled Ezzedine, MD, PhD ^c,^d, Iltefat Hamzavi, MD ^e, Amit G. Pandya, MD ^f, John E. Harris, MD, PhD ^g
on behalf of the
Vitiligo Working Group
^a Department of Dermatology, St. Vincent's Hospital, The Skin and Cancer Foundation Inc, Victoria, Australia
^b The Royal Children's Hospital, Victoria, Australia
^c Department of Dermatology, Henri Mondor Hospital, Creteil, France
^d EpiDermE, Universite Paris-Est, Creteil, France
^e Department of Dermatology, Henry Ford Hospital, Detroit, Michigan
^f Department of Dermatology, University of Texas Southwestern Medical Center, Dallas, Texas
^g Department of Dermatology, University of Massachusetts Medical School, Worcester, Massachusetts

^∗Correspondence to: Michelle Rodrigues, MBBS(Hons), FACD, Department of Dermatology, 41 Victoria Parade, Fitzroy, VIC 3065, Australia.Department of Dermatology41 Victoria ParadeFitzroyVIC3065Australia

Abstract

Clinicians should be aware that vitiligo is not merely a cosmetic disease and that there are safe and effective treatments available for vitiligo. It is important to recognize common and uncommon presentations and those with active disease, as well as their implications for clinical management; these were discussed in the first article in this continuing medical education series. Existing treatments include topical and systemic immunosuppressants, phototherapy, and surgical techniques, which together may serve to halt disease progression, stabilize depigmented lesions, and encourage repigmentation. We discuss how to optimize the currently available treatments and highlight emerging treatments that may improve treatment efficacy in the future.

Le texte complet de cet article est disponible en PDF.

Key words : afamelanotide, biologics, corticosteroids, excimer lamp, excimer laser, grafting, leukoderma, methotrexate, narrowband ultraviolet light, phototherapy, pigmentation, tacrolimus, treatment, vitiligo

Plan

	Supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases, part of the National Institutes of Health, under Award Numbers AR061437 and AR069114, and research grants from the Kawaja Vitiligo Research Initiative, Vitiligo Research Foundation, and Dermatology Foundation Stiefel Scholar Award (to Dr Harris).
	Conflicts of interest: See above.
	Reprints not available from the authors.
	Date of release: July 2017
	Expiration date: July 2020